ConductScience.org, home

Paper8201385

Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.

Michel G and 9 others. J Clin Oncol, 1994. Cited by 70 papers, by iCite.

Cite this record

ConductScience Library. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. Papers, record 8201385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8201385

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
PubMed
Journal
J Clin Oncol
PubMed
Year
1994
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
70
iCite
Relative citation ratio, by iCite
2.46
iCite
Revised in PubMed
2017-02-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Michel GG
2Gluckman EE
3Esperou-Bourdeau HH
4Reiffers JJ
5Pico JLJ L
6Bordigoni PP
7Thuret II
8Blaise DD
9Bernaudin FF
10Jouet JPJ P

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Bone Marrow TransplantationMajor topic
Leukemia, Myeloid, AcuteMajor topic
Whole-Body IrradiationMajor topic
Busulfan
Child
Child, Preschool
Combined Modality Therapy
Cyclophosphamide
Female
Graft vs Host Disease
Humans
Male
Recurrence
Remission Induction
Survival Rate

Source PubMed

Download CSV of topics

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.

PMIDTitleJournalYearIn PapersSource
41949966[Allogeneic hematopoietic stem cell transplantation in children's acute myeloblastic leukemia: Survival and relapse].Tunis Med2025https://conductscience.org/library/papers/41949966PubMed
34546410Neurological complications in Chinese children undergoing hematopoietic stem cell transplantation.Childs Nerv Syst2021https://conductscience.org/library/papers/34546410PubMed
31996791
Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study.
Bone Marrow Transplant2020https://conductscience.org/library/papers/31996791PubMed
31913492
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
JAMA Netw Open2020https://conductscience.org/library/papers/31913492PubMed
31536825
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant2020https://conductscience.org/library/papers/31536825PubMed
30804484Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation.Bone Marrow Transplant2019https://conductscience.org/library/papers/30804484PubMed
25616572Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program.Haematologica2015https://conductscience.org/library/papers/25616572PubMed
25387094Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study.Bone Marrow Transplant2015https://conductscience.org/library/papers/25387094PubMed
24317131
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Bone Marrow Transplant2014https://conductscience.org/library/papers/24317131PubMed
24065243Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Blood2013https://conductscience.org/library/papers/24065243PubMed
23103678Allo-SCT using BU, CY and melphalan for children with AML in second CR.Bone Marrow Transplant2013https://conductscience.org/library/papers/23103678PubMed
22455797Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Clin Pharmacokinet2012https://conductscience.org/library/papers/22455797PubMed
20307709Hematopoietic stem cell transplantation for leukemia.Pediatr Clin North Am2010https://conductscience.org/library/papers/20307709PubMed
19011666Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI.Bone Marrow Transplant2009https://conductscience.org/library/papers/19011666PubMed
18560412Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.Bone Marrow Transplant2008https://conductscience.org/library/papers/18560412PubMed
18223695The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.Bone Marrow Transplant2008https://conductscience.org/library/papers/18223695PubMed
17988993Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.Int J Hematol2007https://conductscience.org/library/papers/17988993PubMed
17563741Autologous bone marrow transplantation for children with AML in first remission.Bone Marrow Transplant2007https://conductscience.org/library/papers/17563741PubMed
16121218
Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.
Leukemia2005https://conductscience.org/library/papers/16121218PubMed
15064687I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.Bone Marrow Transplant2004https://conductscience.org/library/papers/15064687PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8201385

GET https://conductscience.org/api/papers/v1/8201385/cited_by?page=2